Results from a Phase 1 study of GT-02287 in healthy volunteers demonstrated favorable safety and tolerability, plasma and CNS ...
Peer-reviewed study highlights collaboration between University of Ottawa and Spiderwort Biotechnologies Inc. OTTAWA, ON, Dec. 10, 2025 /CNW/ - A new peer-revi ewed study published in Scientific ...
No treatment-related adverse toxicity was observed across completed GLP studies, with consistent systemic exposure following ...
The FDA’s emerging framework represents more than a regulatory update; it is a paradigm shift toward human-relevant, science-forward drug development. By reducing reliance on animal models and ...
Explore the challenges faced by Indian pharma in developing rare disease drugs and potential solutions for innovation and cost reduction.
Xortx Therapeutics announces pioneering research on genome-wide pathogenic pathways in gout: Calgary, Alberta Saturday, January 3, 2026, 13:00 Hrs [IST] Xortx Therapeutics Inc., a ...
New findings suggest that a protein known as Reelin could play a role in treating both “leaky gut” and severe depression.
XORTX Therapeutics Inc. ("XORTX" or the "Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical ...
Learn more about whether Charles River Laboratories International, Inc. or Waters Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback